Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients.

Acute-On-Chronic Liver Failure Clinical Trial

Official title:

Efficacy of Albumin Plus Midodrine v/s Albumin Alone in Reducing Incidence of Paracentesis Induced Circulatory Dysfunctions in ACLF Patients-A Randomized Controlled Trial.

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04474262
• Other study ID #: ILBS-ACLF-06
• Status: Not yet recruiting
• Phase: N/A
• Start date: July 15, 2020
• Est. completion date: March 31, 2021

Study information

• Verified date: June 2020
• Source: Institute of Liver and Biliary Sciences, India
• Contact: Dr Ajay Mishra, MD
• Phone: 01146300000
• Email: ajaymishrapandit[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The patients with ACLF having Ascites who require ascitic tapping will undergone ascitic tapeither under albumin cover alone or with midodrine. The patient will be monitored for complication and changes of PICD. Study analysis will be done with primary objective being reduction in incidence of PICD.

Description:

OBJECTIVE:

Primary objective: Incidence of Paracentesis induced circulatory dysfunction in patients undergoing modest volume paracentesis (MVP) (>3 and <5 litres) with midodrine plus 25% albumin v/s 25% albumin infusion alone at day 7

Secondary objective:

• Change in systolic, diastolic and mean BP at day 3 and 6

• Increase in plasma renin activity at day 6

• Incidence of Hyponatremia, HE and AKI at day 3 and 6

• Predictors of Paracentesis induced circulatory dysfunction

• Predictors of 28 day survival.

Methodology :

Patients with Acute on chronic liver failure having grade III ascites will be given either albumin or albumin plus midodrine. Midodrine will be started 4 hrs before tap to achieve target MAP. Ascitic tapping will be followed by vital monitoring and monitoring of vital parameters along with measurement of changes in s. rennin at day 3 and 6.

• All patient will be undergo complete physical examination and complete clinical history will be recorded.

• Baseline cbc,LFT,KFT and INR level will be sent on day 1 along with baseline s. renin levels

• Those eligible will be randomised in to two groups

• GROUP A will be given albumin 8g/l of ascitic tap during tap along with placebo for 7 days.

• GROUP B will be given midodrine 7.5 mg to 12.5 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.

Study Population: Patients of acute on chronic liver failure who are admitted to and attending the OPD at ILBS.

Study Design: Randomized controlled trial Study Period:NOV 2019 to march 2019

Sample Size:

Considering incidence of PICD in albumin group is 30% and reduction to 10% by adding midodrine with alpha =5%, and power of study being 80%. No. of cases in each group- 66 Total-132 Furthur with 10% dropout we need to enroll 150 cases (75 in each group) randomly allocated in two groups by block randomization method with block size of 5.

• Intervention: This RCT will be conducted at ILBS New Delhi between Dec 2019 and March 2021

• Monitoring and assessment:

• All patient will be undergo complete physical examination and complete clinical history will be recorded.

• Baseline cbc,LFT,KFT and INR level will be sent on day 1 along with baseline s. renin levels

• Those eligible will be randomised in to two groups

• GROUP A will be given albumin 8g/l of ascitic tap along with placebo for 7 days. Standard albumin therapy will continue (40gm/week)

• GROUP B will be given midodrine 7.5 mg to 10 mg tds (keeping the target MAP above 70 mmhg)for 7 days plus albumin same as in other group.

Expected outcome of the project:

Primary:

• Incidence of PICD at day 3 and day6

Secondary:

• Changes in hemodynamic parameters at 1, 3 and 6 hour, Day 3, Day 6 post paracentesis

• Increase in plasma renin activity at Day 3, Day 6

• Incidence of Hyponatremia, HE and AKI at day 3 and 6

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 150
• Est. completion date: March 31, 2021
• Est. primary completion date: March 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• ACLF patients (as per APASL definition) with grade II/III ascites

Exclusion Criteria:

1. Age < 18 or >75 years

2. Hepatocellular carcinoma

3. Extrahepatic portal vein obstruction

4. Non cirrhotic ascites

5. Serum creatinine >1.5mg/dl

6. Refractory septic shock

7. Beta blockersPortal vein thrombosis

8. Grade 3-4 HE

9. Pregnancy or Lactation

10. Active variceal bleed

11. Respiratory, cardiac, renal failure

12. Uncontrolled hypertension

13. Severe coagulopathy

14. Refusal to participate

Related Conditions & MeSH terms

• Acute-On-Chronic Liver Failure
• End Stage Liver Disease
• Liver Failure

Intervention

Biological:
• Albumin
Albumin will be 8g/l of ascitic tap. Standard albumin therapy will continue (40gm/week)

Drug:
• Midodrine Oral Tablet
Midodrine 7.5 mg to 10 mg TDS (keeping the target MAP above 70 mmHg).

Other:
• Placebo
Placebo

Locations

Country	Name	City	State
India	Institute of Liver & Biliary Sciences	New Delhi	Delhi

Sponsors (1)

Lead Sponsor	Collaborator
Institute of Liver and Biliary Sciences, India

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of PICD (Paracentesis Induced Circulatory Dysfunction)		Day 3
Primary	Incidence of PICD (Paracentesis Induced Circulatory Dysfunction)		Day 6
Secondary	Changes in Mean Arterial Pressure (MAP) post paracentesis.		1 hour
Secondary	Changes in Heart Rate post paracentesis.		1 hour
Secondary	Changes in Mean Arterial Pressure (MAP) post paracentesis.		3 hours
Secondary	Changes in Heart Rate post paracentesis.		3 hours
Secondary	Changes in Mean Arterial Pressure (MAP) post paracentesis.		6 hours
Secondary	Changes in Heart Rate post paracentesis.		6 hours
Secondary	Changes in Mean Arterial Pressure (MAP) post paracentesis.		Day 3
Secondary	Changes in Heart Rate post paracentesis.		Day 3
Secondary	Changes in Mean Arterial Pressure (MAP) post paracentesis.		Day 6
Secondary	Changes in Heart Rate post paracentesis.		Day 6
Secondary	Change in plasma renin activity in both groups		Day 3
Secondary	Change in plasma renin activity in both groups		Day 6
Secondary	Incidence of Hyponatremia in both groups		Day 3
Secondary	Incidence of Hyponatremia in both groups		Day 6
Secondary	Incidence of Hepatic Encephalopathy in both groups		Day 3
Secondary	Incidence of Hepatic Encephalopathy in both groups		Day 6
Secondary	Incidence of Acute Kidney Injury in both groups		Day 3
Secondary	Incidence of Acute Kidney Injury in both groups		Day 6